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ABSTRACT
Background: An impaired HBsAg-secretion can increase HBV oncogenic-
properties. Here, we investigate genetic-determinants in HBsAg correlated with HBV-
induced hepatocellular carcinoma (HCC), and their impact on HBsAg-secretion and 
cell-proliferation.
Methods: This study included 128 chronically HBV-infected patients: 23 with HCC 
(73.9% D; 26.1% A HBV-genotype), and 105 without cirrhosis/HCC (72.4% D, 27.6% 
A) as reference-group. The impact of mutations on HBsAg-secretion was assessed 
by measuring the ratio [secreted/intracellular HBsAg] until day 5 post-transfection. 
The impact of mutations on cell-cycle advancement was assessed by flow-cytometry.
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Results: Two HBsAg mutations significantly correlated with HCC: P203Q (17.4% 
[4/23] in HCC vs 1.0% [1/105] in non-HCC, P=0.004); S210R (34.8% [8/23] in 
HCC vs 3.8% [4/105] in non-HCC, P <0.001); P203Q+S210R (17.4% [4/23] in HCC 
vs 0% [0/110] in non-HCC, P=0.001). Both mutations reside in trans-membrane 
C-terminal domain critical for HBsAg-secretion. In in-vitro experiments, P203Q, S210R 
and P203Q+S210R significantly reduced the ratio [secreted/intracellular HBsAg] 
compared to wt at each time-point analysed (P <0.05), supporting an impaired 
HBsAg-secretion. Furthermore, P203Q and P203Q+S210R increased the percentage 
of cells in S-phase compared to wt, indicating cell-cycle progression (P203Q:26±13%; 
P203Q+S210R:29±14%; wt:18%±9, P <0.01. Additionally, S210R increased the 
percentage of cells in G2/M-phase (26±8% for wt versus 33±6% for S210R, P 
<0.001).
Conclusions: Specific mutations in HBsAg C-terminus significantly correlate 
with HBV-induced HCC. They hamper HBsAg-secretion and are associated with 
increased cellular proliferation, supporting their involvement in HCC-development. 
The identification of viral genetic markers associated with HCC is critical to identify 
patients at higher HCC-risk that may deserve intensive liver monitoring, and/or early 
anti-HBV therapy.
INTRODUCTION
Hepatocellular carcinoma (HCC) is one of the 
most frequent solid tumors and the third cause of cancer 
death worldwide [1, 2]. This cancer is rapidly fatal in the 
majority of patients with advanced liver disease. Recent 
estimates attribute to hepatitis B virus (HBV) over 50% 
of HCC cases worldwide. The lifetime risk of developing 
HCC is 10- to 100- fold greater for chronic HBV carriers 
than non-infected individuals. In addition, individuals with 
clinically resolved HBV infection have a risk to develop 
HCC ≈ 3-fold greater than uninfected populations. In 
contrast with HCV, a substantial number of HBV-infected 
patients develops HCC without any sign of liver damage 
[3], highlighting the existence of intrinsic HBV-mediated 
pro-oncogenic mechanisms [1, 4-9].
At this moment, there is paucity of diagnostic tools 
able to predict the development of HCC; still today, the 
prevention is based essentially on ultrasound-driven early 
diagnosis of cancer development. Despite this effort, 
the prognosis of HCC remains poor [10]. This strongly 
highlights the need to identify patients at higher risk to 
develop HCC in order to set up a more intensive liver 
monitoring and/or an early treatment [11, 12].
Viral genetic variability plays an important role 
in potentiating HBV pro-oncogenic properties. Several 
studies have correlated the presence of mutations in HBV 
genomic region known as basal core promoter and HBx 
with an increased risk to develop HCC [13-16]. A growing 
number of studies is also pointing out the role of HBV 
surface antigen in mechanisms underlying HBV-related 
carcinogenesis [5].
The S-gene is composed by pre-S1, pre-S2, and 
S region, coding for the three forms of HBV surface 
glycoproteins: the small-sized HBV surface antigen 
(S-HBsAg), the medium-sized (M-HBsAg, pre-S2+S) 
and large-sized surface antigen (L-HBsAg, pre-S1+pre-
S2+S). HBV surface proteins (L-HBsAg, M-HBsAg, and 
S-HBsAg) are synthesized in the endoplasmic reticulum 
where they rapidly undergo dimer and multimer formation 
via extensive disulphide bonding. This results in budding 
into the endoplasmic reticulum as either spherical or 
filamentous empty subviral particles (mainly composed by 
S-HBsAg), or as virions [17]. Stop codons in S-HBsAg as 
well as deletions in L-HBsAg and M-HBsAg have been 
associated with the production of truncated or structurally-
modified surface antigens, that own a dominant negative 
secretion defect, and accumulate inside the hepatocytes 
[8, 18, 19]. The intracellular accumulation of unfolded or 
misfolded HBV surface antigens exerts cytotoxic effects, 
activating intracellular signaling pathways associated with 
oxidative stress, thus promoting cell transformation [7, 8]. 
Beyond deletions and stop-codons, paucity of information 
is available on point mutations in surface antigens 
correlated with HCC.
Among the different S-HBsAg domains, the 
C-terminus (from amino acid [aa] 179 to 226) is 
hydrophobic and is assumed to be inserted in the 
endoplasmic reticulum membrane [20]. This domain 
is involved in mediating the transit of the surface 
glycoproteins across the endoplasmic reticulum 
[21]. Mutations in this domain can result in a stable, 
glycosylated, but non-secreted chain, thus affecting the 
biogenesis and secretion of subviral particles [21]. Thus, it 
could be hypothesized that mutations in this domain could 
promote an intra-cellular accumulation of S-HBsAg and in 
turn contribute to promote cell proliferation [1, 5, 22]. So 
far, no studies have addressed this issue.
Based on this rationale, this study is aimed 
at evaluating i) the correlation of mutations in the 
C-terminus S-HBsAg domain with HBV-induced HCC, 
ii) the impact of these mutations on HBsAg secretion, iii) 
Oncotarget15706www.impactjournals.com/oncotarget
the impact of these mutations on cell-cycle progression. 
The identification of these viral markers is critical in 
order to identify patients at higher risk to develop this 
deadly disease that need an early treatment and/or a more 
intensive liver monitoring. This represents an unmet 
medical need, fully answering to the issue “assess host 
genetic and viral markers to determine prognosis and 
optimise patients' management” raised by European HBV 
Guidelines promoted by the European Association for the 




This study included 23 patients with a diagnosis of 
HBV-induced HCC (Table 1). Most patients were male 
(91.7%), with a median (interquartile range [IQR]) age 
of 63 (53-70) years (Table 1). At HCC diagnosis, median 
(IQR) HBV-DNA was 4.0 (2.1-6.5) log IU/ml and median 
(IQR) ALT and AST was 82 (28-112) and 50 (33-139) 
IU/L, respectively (Table 1). Notably, 47.8% of patients 
received HCC diagnosis in a condition of low-grade liver 
disease (Child-Pugh class A), and 34.8% developed HCC 
in absence of liver cirrhosis (Table 1). At HCC diagnosis, 
most patients showed an elevated level of alpha-
fetoprotein (AFP) (median [IQR] serum AFP: 519[6.2-
13,012] ng/ml) (Table 1). In most patients (60.9%), 
liver imaging showed the presence of a single-nodule 
HCC, with a median (IQR) size of 5 (2.5-7.6) cm, while 
in 30.4% of patients a multi-focal HCC was diagnosed 
(Table 1). Among 17 patients suitable for HCC treatment, 
trans-catheter arterial chemoembolisation (TACE) was the 
most used strategy for HCC treatment (in 8/17 [47.1%]) 
while in 4/17 (23.5%) the progression of HCC required 
to be treated with a surgical resection (Table 1). At HCC 
diagnosis, 60.9% of patients were treated with a nucleos(t)
ide analogues (NUCs) (Table 1).
HBsAg mutations associated with  
HBV-related HCC
The correlation of mutations in the C-terminus 
region of S-HBsAg was investigated. A group of 105 
patients with chronic hepatitis B and no clinical evidence 
of cirrhosis and hepatocellular carcinoma was used as 
reference. These patients had comparable virological 
parameters in terms of serum HBV-DNA, percentage 
of HBeAg negativity, HBV genotype distribution and 
experience of anti-HBV therapy (Table 1).
Two specific mutations (sP203Q and sS210R) were 
significantly correlated with the presence of HCC (Figure 
1). sP203Q occurred in 17.4% (4/23) of HCC-patients 
versus 1.0% (1/105) of patients without HCC (P=0.004) 
(Figure 1). Similarly, sS210R was found in 34.8% (8/23) 
of HCC-patients and in 3.8% (4/105) of patients without 
HCC (P <0.001) (Figure 1). In particular, the double 
mutant sP203Q+sS210R was detected exclusively in 
HCC-patients (17.4% [4/23] versus 0% [0/105], P=0.001) 
(Figure 1). sP203Q occurred as a mixture in 2/4 HCC 
patients while sS210R occurred as a mixture only in 1 
patient. By analysing the overlapping between the HBsAg 
and RT genes, sP203Q did not result in any amino acid 
substitution in RT, while sS210R corresponded to rtS219A. 
This mutation is localized in an RT region (whose function 
has not been defined yet) between the RT domains C (aa: 
200-210) and D (aa: 230-241). The percentage of patients 
with sS210R/rtS219A was comparable between drug naïve 
HCC-patients (33.3%, 3/9) and drug-treated HCC-patients 
(35.7%, 5/14), thus excluding the impact of antiviral 
therapy on the selection of this mutation.
Multivariate analysis confirmed that the presence of 
either sP203Q or sS210R was independently associated 
with a higher probability of developing HCC (adjusted 
Odd-Ratio [95% C.I.]: 12.0 [1.6-78.8], P=0.02), after 
correction for patients' age, gender, HBV genotype, serum 
HBV-DNA, ALT and AST (Table 2).
Furthermore, multifocal HCC was found to occur 
more frequently in patients with either P203Q or S210R 
(4/8 [50%]) than in patients without these mutations 
(3/15 [20%]). In line with this datum, the level of alpha-
fetoprotein (AFP) at HCC diagnosis was higher in patients 
with either P203Q or S210R than in patients without these 
mutations (median [IQR] AFP: 6500 [212–18250] ng/mL 
vs 58 (7-2139) ng/mL). No other mutations in C-terminus 
of HBsAg resulted significantly correlated with HCC.
Previous studies have correlated the presence of 
deletions in the preS1 and preS2 regions in S gene with 
an increased HBV oncogenic potential [5]. Thus, the 
presence of pre-S1 and pre-S2 deletions was investigated, 
as well as their co-occurrence with sP203Q or sS210R. 
Pre-S1 and Pre-S2 deletions were found in 3/23 (13.0%) 
HCC-patients and in 6/105 (5.7%) controls (P=0.2). No 
deletions were found with sP203Q or sS210R in both HCC 
and control group. This suggests that sP203Q/sS210R in 
HBsAg C-terminus and deletions in pre-S1 and pre-S2 lie 
on divergent evolutionary pathways contributing to HCC 
development.
Data from UDPS: intra-patient prevalence of 
mutations associated with HCC
UDPS analysis was performed in 13 HCC patients 
(6/13 carrying sP203Q or sS210R by population-based 
sequencing) and 27 reference patients (2/27 carrying 
sP203Q or SS210R by population-based sequencing) 
(Figure 2). In HCC patients, sP203Q and/or sS210R 
occurred with a median (IQR) intrapatient prevalence of 
70.6% (12.7%-100%). sP203Q never occurred as single 
mutation but only in association with sS210R, with an 
intrapatient ranging from 86.7% to 100% (Figure 2A). 
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Table 1: Characteristics of the study population
Patients’ characteristics HCC patients(N=23)
Control patients
(N=105)
Male, N(%) 21 (91.7) 80 (76.2)
Italian Nationality, N(%) 16 (69.6) 89 (84.8)
Median Age [Years] (IQR) 63 (53-70) 51 (41-65)
HBeAg negative, N(%)a 14 (77.8) 62 (78.5)
Median HBV-DNA [log IU/ml] (IQR) 4.0 (2.1-6.5) 4.1 (3.1-5.4)
Median ALT [IU/L] (IQR) 82 (28-112) 49 (29-90)
Median AST [IU/L] (IQR) 50 (33-139) 35 (23-58)
HBV Genotype
D, N(%) 17 (73.9) 76 (72.4)
A, N(%) 6 (26.1) 29 (27.6)
Anti-HBV Therapy
None, N(%) 9 (39.1) 45 (42.9)
LMV, N(%) 6 (26.1) 30 (28.6)
ETV, N(%) 3 (13.0) 3 (2.9)
TDF, N(%) 3 (13.0) 15 (14.3)
ADV, N(%) 1 (4.4) 9 (8.6)
LMV+ADV, N(%) 1 (4.4) 3 (2.9)
HCC characteristics
Single Nodule HCC, N(%) 14 (60.9)
Multifocal-HCC, N(%) 7 (30.4)
Unknown, N(%) 2 (8.7)
Tumor size
Median size of each HCC nodule [cm] (IQR) 5 (2.5-7.6)
Median alfa-feto protein at HCC diagnosis 
(IQR), ng/ml 519 (6.2-13,012)
Portal Invasion
Yes, N(%) 5 (21.7)
No, N(%) 14 (60.9)
Unknown, N(%) 4 (17.4)
Capsular Formation
Yes, N(%) 7 (30.4)
No, N(%) 7 (30.4)
Unknown, N(%) 9 (39.2)
HCC treatment
TACE, N(%) 8 (34.8)
Surgical resection, N(%) 4 (17.4)
Thermoablation, N(%) 2 (8.7)
No, N(%) 3 (13.0)
Unknown, N(%) 6 (26.1)
Liver status
Diagnosis of cirrhosis, N(%) 15 (65.2)
(Continued )
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Conversely, in chronically infected control patients, the 
median [IQR] intra-patient prevalence of these HBsAg 
mutations, found associated with HCC, was remarkably 
lower (15.8% [10.6%-23.8%]) (Figure 2B).
Impact of sP203Q, sS210R and sP203Q+sS210R 
mutations on the extracellular on intracellular 
HBsAg ratio
The next step of this study was to investigate the 
impact of sP203Q, sS210R and sP203Q+sS210R on 
HBsAg release. For this purpose, the ratio of extracellular 
on intracellular HBsAg was measured for the wild-type 
virus and each mutant. This ratio was defined as HBsAg 
secretion factor.
All three mutants carrying sP203Q, sS210R, and 
sP203Q+sS210R determined a reduction of HBsAg 
secretion factor compared to wild-type at each time-point 
analyzed (P <0.05) (Figure 3A). In particular, at day 4 of 
culture (characterized by the peak in HBsAg production), 
HBsAg secretion factor decreased from 4.42±0.3 for wild-
type to 2.22±0.2 for P203Q (P <0.001), to 3.52±0.2 for 
S210R (P <0.05), and to 2.33±0.2 for P203Q+S210R (P 
<0.01) (Figure 3A). These results reflects the ability of 
sP203Q, sS210R and sP203Q+sS210R to negatively affect 
HBsAg release.
Impact of sP203Q, sS210R and sP203Q+sS210R 
mutations on cell proliferation
The impact of sP203Q, sS210R and 
sP203Q+sS210R on cell proliferation was then evaluated 
by flow cytometry (DNA propidium iodide-staining) on 
transfected GFP+ cells at day 7 post transfection (Figure 
3B). In this analysis, sP203Q and sP203Q+sS210R 
significantly correlated with an increased percentage 
of cells in the S phase of cellular cycle, thus supporting 
an induction of cell cycle progression (Figure 3B). In 
particular, the percentage of cells in the S phase at 7 days 
post transfection increased from 18%±9 for wild-type up 
to 26±13% for P203Q and 29±14% for P203Q+S210R 
(P <0.001 for both) (Figure 3B). Conversely, sS210R 
significantly correlated with an increased percentage 
of cells in the G2/M phase of cellular cycle (26±8% for 
wild type versus 33±6% for sS210R, P <0.001), thus 
supporting an induction of cell cycle progression and cell 
division (data not shown). Notably, cells transfected with 
HBsAg plasmid carrying the mutation sS210R showed 
increased intracellular levels of cyclin A, compared to 
those transfected with wild type HBsAg (fold compared to 
mock = 2.1±0.08 versus 1.7±0.04 for wt). No differences 
in intracellular cyclin levels were observed in hepatoma 
cells transfected with plasmid carrying P203Q and 
P203Q+S210R HBsAg mutations compared to wt (fold 
compared to mock = 1.8±0.2 and 1.8±0.1 versus 1.7±0.04 
for wt, respectively). Therefore, the sS210R mutants 
within C-terminal HBsAg might contribute to cell cycle 
progression by modulating the expression of cyclin A.
DISCUSSION
This study shows that sP203Q and sS210R 
mutations, in HBsAg C-terminal domain (aa 179 to 226), 
significantly correlate with the presence of HBV-induced 
HCC. By multivariable analysis, the presence of at least 1 
of these mutations is an independent factor significantly 
correlated with HCC, after correction for both viral and 
patients' parameters. In addition, the prevalence of these 
mutations is comparable between drug naïve and drug 
treated HCC-patients, excluding the role of antiviral 
treatment on their selection. In in-vitro experiments, these 
mutations determine a reduction in the extracellular/
intracellular HBsAg ratio, supporting their ability to 
hamper HBsAg secretion. In addition, sP203Q correlates 
with an increased percentage of cells in S phase, while 
sS210R with an increased percentage of cells in G2/M 
phase of cell cycle compared to wild-type, highlighting 
their ability to promote cell-cycle advancement and/or 
cell proliferation. To support this finding, the presence of 
these mutations is also correlated with increased levels 




A, N(%) 11 (47.8)
B, N(%) 6 (26.1)
C, N(%) 2 (8.7)
Unknown, N(%) 4 (17.4)
a The percentages were calculated on 18 HCC and 79 control patients with an available HBeAg status.
Abbreviations: HCC, Hepatocellular carcinoma; HBeAg, Hepatitis B “e” antigen; ALT, Alanine Aminotransferase; AST, 
aspartare aminotrasferase; TACE, Transcatheter arterial Chemoembolisation; LMV, lamivudine; ETV, entecavir; TDF, 
tenofovir disoproxil fumarate; ADV, adefovir.
Oncotarget15709www.impactjournals.com/oncotarget
of AFP in vivo (a well known marker of hepatocellular 
proliferation). Overall data support the involvement of 
these two mutations in mechanisms underlying HBV 
oncogenic properties. In addition, in a patient carrying 
the mutation sS210R, a pre-HCC HBV sequence was 
available and confirmed the presence of this mutation 
already 1 year before the diagnosis of HCC, further 
supporting the role of this mutation in promoted HBV-
mediated hepatocarcinogenesis.
The identification of viral genetic markers associated 
with HCC is critical to identify patients at higher HCC-
risk that may deserve intensive liver monitoring, and/or 
early anti-HBV therapy. At the same time, this may allow 
to reduce the elevated costs associated with the clinical 
management of patients with HCC. This represents an 
unmet medical need, fully answering to the issue “assess 
host genetic and viral markers to determine prognosis and 
optimise patients' management” raised by European HBV 
Guidelines promoted by the European Association for the 
Study of the Liver (EASL) (http://www.easl.eu/research/
our-contributions/clinical-practice-guidelines).
Previous studies have investigated the role of stop-
codons in S-HBsAg in mechanisms underlying HBV-
induced tumorigenesis [2, 19, 25]. They showed that stop-
codons (at S-HBsAg position 172, and 182) can determine 
the production of truncated S-HBsAg that can be retained 
inside the hepatocytes, thus promoting metabolic 
alterations associated with neoplastic transformation of 
the hepatocytes [1, 2, 19, 25].
This is the first study showing the involvement of 
specific point mutations, within S-HBsAg C-terminus, 
in HCC development. During HBV life cycle, HBsAg 
C-terminus is embedded in the membrane of the endoplasmic 
reticulum and plays an important role in the biosynthesis and 
release of sub-viral particles [21]. In particular, Bruss and 
Ganem found that deletions in the S-HBsAg C-terminus 
hamper the budding or intracellular transport of sub-viral 
particles [21]. In our study, the presence of sP203Q and 
sS210R in HBsAg C-terminus determines a decrease of 
the extracellular on intracellular HBsAg ratio, reflecting 
the ability of these mutations to affect HBsAg secretion. 
Notably, sP203Q and sS210R introduce a negatively and 
positively charged amino acid, respectively. It is conceivable 
that the acquisition of charged amino acids can obstacle the 
proper folding of HBsAg C-terminus in the endoplasmic 
reticulum membrane, thus impairing HBsAg release 
and resulting in its accumulation in specific intracellular 
compartments (presumably represented by endoplasmic 
reticulum/Golgi apparatus). In line with this hypothesis, 
a previous study showed that the sS204R mutation in 
S-HBsAg C-terminus (along with G145R) exhibited a viral 
secretion defect compared to the wild-type [26].
HBsAg retention within hepatocytes is a mechanism 
known to promote the initiation of HBV-driven 
carcinogenesis by activation of endoplasmic reticulum-
stress-signaling dependent pathways [1, 27-29]. In line 
with this concept, we found that the presence of sP203Q 
and sS210R increases the % of cells in S- and G2/M phase 
of cell cycle, respectively, suggesting their contribution 
to the advancement of cell cycle that may pose the basis 
for an increased cell proliferation. Again, no studies have 
previously addressed this issue.
Figure 1: The histogram reports the prevalence of sP203Q, sS210R, and sP203Q+sS210R in 23 HBV-induced HCC 
patients and in 105 chronically HBV-infected patients (CHB patients) (used as reference group). Statistically significant 
differences were assessed by Fisher Exact Test. * P <0.05, ** P <0.01.
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Figure 2: The graph reports the intra-patient prevalence of sP203Q (white dots), sS210R (grey dots), sP203Q+sS210R (black dots) 
for each patient in the HCC group (N=13) A. and in the group of chronically-infected patients used as reference (N=27) B. Intra-patient 
prevalence was expressed as % of reads with the specific mutation. The grey area includes mutations with an intra-patient prevalence <20%, 
not detected by standard population-based sequencing, and thus defined as minority species.
Table 2: Multivariate analysis: factors associated with HCC
Variablesa
Univariate analysis Multivariate analysis
crude OR [95% CI] p-value adjusted OR [95% CI] p-value
Gender (Female vs. 
Maleb) 0.30 (0.07-1.39) 0.125 0.27 (0.04-1.96) 0.197
Age (for 1 year 
increase) 1.06 (1.02-1.10) 0.004 1.06 (1.01-1.12) 0.019
Year (for 1 year 
increase) 0.96 (0.84-1.09) 0.499 0.99 (0.83-1.18) 0.902
HBV-DNA (log10) 0.98 (0.77-1.25) 0.857 0.91 (0.66-1.26) 0.588
ALT 0.98 (0.97-1.01) 0.993 0.99 (0.98-1.01) 0.212
AST 1.01 (0.98-1.02) 0.422 1.01 (0.99-1.03) 0.188
Genotype (A vs Db) 0.92 (0.33-2.58) 0.881 0.85 (0.19-3.73) 0.826
At least one mutation 
(P203Q+/-S210R) 13.47 (3.61-50.27) <0.0001 6.45 (1.37-30.43) 0.019
a The logistic regression analysis was performed on 128 chronically HBV-infected patients with or without HCC. The 
following variables were considered: gender, year of sample collection, age, HBV-DNA log10, ALT, AST, HBV genotype, 
at least one mutation associated with HCC.
b Reference group
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The increased amount of cyclin A observed in 
vitro for the mutant sS210R corroborates the impact of 
this mutation on cell cycle progression. Indeed, cyclin 
A plays an important role in the S and G2/M phases 
checkpoint of the cell cycle [30]. Several studies [31, 
32] have demonstrated that an upregulation of cyclin A 
causes an impaired control of cell cycle progression, that 
contribute to the oncogenic transformation of hepatocytes. 
In literature, the overexpression of cyclin A was reported 
to link malignant features not only in hepatocellular 
carcinoma but also in prostate, colorectal and renal cell 
cancers [33-35].
Figure 3: A. The histogram reports HBsAg secretion factor for the wild-type virus and for mutants carrying P203Q, S210R and 
P203Q+S210R. Secretion factor is defined as the ratio of extracellular to intracellular HBsAg amount determined by the Alexxis assay. 
Average of 3 experiments +/- SEM are shown. Statistically significant differences were assessed by 2-tailed unpaired T-test. *P <0.05 **P 
<0.01, ***P <0.005. B. The histogram reports the percentage of cells in S-phase of cell cycle for wild-type and mutants at 7 days post 
transfection determined by FACS analysis, selecting GFP+ HepG2 cells. Statistical analysis was assessed by Chi-Square Test based on 2x2 
contingency table. *P <0.001
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Previous studies have correlated the presence of 
deletions in the preS1 and preS2 regions in S gene with an 
increased HBV oncogenic potential [5, 36]. In our study, 
no deletions were found in HCC-patients with sP203Q or 
sS210R. This may suggest that the co-presence of sP203Q/
sS210R in HBsAg C-terminus and deletions in pre-S1 
and pre-S2 may be lethal for HBV replication. At the 
same time, this may also suggest that sP203Q or sS210R 
and deletions in pre-S1/pre-S2 may lie on divergent 
evolutionary pathways contributing to HCC development.
This study was conducted in patients infected with 
HBV genotype D and A. Therefore, these results should 
be seen in the context of genotype D/A, and additional 
studies are required to evaluate whether these mutational 
pathways lead to similar conclusions also in other HBV 
genotypes, whose oncogenic potential has been well 
demonstrated.
In conclusions, specific mutations, residing in 
C-terminal HBsAg domain, are highly correlated with 
HBV-induced HCC in vivo. They affect HBsAg secretion 
and stimulate cell proliferation in vitro, supporting their 
involvement the initiation of HBV-driven carcinogenesis. 
The identification of viral genetic markers associated with 
HCC is critical to identify patients at higher HCC-risk that 




This study included 128 chronically HBV-
infected patients (93 genotype D and 35 genotype A): 
23 consecutive patients with HBV-related HCC and 105 
randomly-selected patients with no clinical evidence of 
cirrhosis and hepatocellular carcinoma (used as reference 
group), followed in different clinical centers in Italy and 
in France from 2004 to 2014. The distribution of HBV 
genotype D and A in HCC- and non-HCC patients was 
comparable (73.9% and 26.1% in patients with HCC 
versus 72.4% and 27.6% in patients without HCC, 
respectively), minimizing the possible influence of HBV 
genotypes in the analysis of the two population groups.
HBV-related HCC cases were included in the study 
according to a radiological or histological diagnosis of a 
hypervascular liver tumor mass (> 1 liver cancer nodule) 
in patients with a previously diagnosed HBV-chronic 
infection. Histological staging of liver tumors was assessed 
according to the WHO grading system. Chronically HBV-
infected patients had no clinical evidence of cirrhosis 
and hepatocellular carcinoma. No patients (0/128) had a 
co-infection with human immunodeficiency virus (HIV), 
hepatitis delta virus (HDV) and hepatitis C virus (HCV).
Ethic approval was deemed unnecessary because, 
under Italian law, biomedical research is subjected to 
previous approval by ethics committees only in the 
hypothesis of clinical trials on medicinal products for 
clinical use (art. 6 and art. 9, leg. decree 211/2003). The 
research was conducted on viral DNA samples (used 
for clinical routine), and data previously anonymized, 
according to the requirements set by Italian Data Protection 
Code (leg. decree 196/2003). Thus, all the plasma samples 
used in this study were archival, and not collected for this 
study. Patient data were stored anonymously in a database 
including genotypic, demographic, biochemical and 
virologic parameters.
Population-based sequencing of the full-length 
S-gene (pre-S1, pre-S2, and S)
The population-based sequencing of the full-length 
S-gene was performed on plasma samples, following a 
home-made protocol, as previously described [23, 24]. 
Details on such protocol are reported in Supplementary-
text I. The population-based sequencing of S gene was 
performed on the plasma samples closest to the diagnosis 
of HCC (never exceeding 12 months after HCC diagnosis).
Sequences having a mixture of wild-type and mutant 
residues at single positions were considered to have the 
mutant(s) at that position.
HBV ultra-deep pyrosequencing (UDPS)
The extent of genetic heterogeneity in S-gene was 
also investigated by UDPS (Roche 454-Junior), according 
to the methodology described in Salpini et al., Hepatology 
2015 [24]. Details on such protocol are reported in 
Supplementary-text II.
UDPS was performed for 13 out of the 23 HCC 
cases and for 27 out of the 105 reference patients, included 
in the study, on the basis of the availability of plasma 
samples. In HCC-patients, no statistically significant 
differences in clinical and demographic characteristics, 
as well as in the prevalence of mutations associated with 
HCC were found after stratification for UDPS availability 
(Supplementary Table 1). Similarly, in the reference 
group, all the demographic and clinical characteristics 
were comparable after stratification for UDPS availability 
(Supplementary Table 1).
Association of mutations with HCC
S-HBsAg sequences obtained by population-
based sequencing were used to assess the association 
of specific mutations in C-terminus with HBV-related 
HCC. Mutations were defined according to the reference 
sequence of each specific HBV genotype (reference 
sequences: X65259.1 and X02763.1 for D and A 
genotypes, respectively). In particular, the prevalence 
of each mutation was calculated in the group of HCC-
patients and in the group of chronically HBV-infected 
patients. Fisher exact test was performed to verify whether 
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the differences in frequency between the two groups of 
patients were statistically significant.
In order to support their correlation with HBV-
related HCC, a logistic regression analysis was performed 
using the statistical open source environment R (version 
3.1.1). The following variables were considered: gender, 
year of sample collection, age, nationality, HBV-DNA 
log10, ALT, AST, HBV genotype, at least one mutation 
associated with HCC. After stepwise elimination for 
optimized Akaike information criterion (AIC), only 
variables showing a p-value < 0.200 in univariate analysis 
were included in the multivariate analysis.
The sequences obtained by UDPS were used to 
define the intra-patient prevalence of mutations associated 
with HBV-related HCC.
Cells
Huh7 and HepG2 cells were cultured in T25 flask 
(Costar) at a density of 5×105 cells/ml in DMEM (High 
glucose - SIGMA) supplemented with 100 U/ml penicillin 
+ 100μg/ml streptomycin, 2 mM GlutaMAX, and 10% fetal 
bovine serum (FBS) heat inactivated. Cells were grown in a 
37°C humidified atmosphere containing 5% CO2.
Plasmids, transfection and HBsAg  
quantification
S-HBsAg mutations associated with HCC were 
introduced into a 1.3x genome-length HBV genotype 
D, HBeAg negative clone using primers as previously 
described [2]. Primers used for mutagenesis were reported 
in Supplementary-text III.
Clones encoding the mutations associated with 
HCC, as well as wild-type (wt) HBV, were transfected 
into Huh7 cells by using Fugene 6 (Promega) according to 
manufacturer. Both cells lysates and cultures supernatants 
were harvested in triplicate daily, from day 2 to day 6 
post-transfection, and HBsAg quantified using Alexxis 
qHBsAg assay. HBsAg from supernatants represents 24 
hours of accumulation.
The plasmid pCMV-HBV (containing an HBV 
genotype-D genome, serotype ayw) was used as 
substrate to amplify the full-length S-gene by using 
the Expand High Fidelity PCR System (Roche) and 
the following primers: F- 5'-GGGGGG AGATCT 
ATGGGGCAGAATCTTTCCAC-3' and R- 5'-GGGGGG 
GTCGAC TTAAATGTATACCCAAAGAC-3'. The 
resulting PCR product was digested with BglII and SalI 
restriction enzymes and subcloned in the corresponding 
sites of the pIRES2-EGFP expression vector (Clontech) 
generating the pIRES/ HBsAg plasmid. This plasmid 
encodes the three forms of HBsAg (L-HBsAg, M-HBsAg, 
S-HBsAg) and the green fluorescent protein (GFP) from 
the same bicistronic mRNA transcript. Western blotting 
was used to assess the expression of HBsAg and of the 
endogenous gene GAPDH by using the following antibodies: 
Anti-Hepatitis B Virus Surface antigen (ABCAM) and anti-
GAPDH antibody (Millipore) (Supplementary Figure 1).
Mutations associated with HCC were also 
introduced into a pIRES/ HBsAg plasmid according to the 
manufacturer instruction (QuikChange II XL Site-Directed 
Mutagenesis Kit, Agilent). HepG2 cells were transfected 
with pIRES-HBsAg plasmid encoding for wt and HBsAg 
mutants 24hours post cells plating by using the reagent 
Transit 2020 (MIRUS Bio). Cells were harvested after 
7 days post transfection. Transfection efficiency was 
monitored by cotransfection of a vector expressing 
Secreted-Alkaline-Phosphatase (SEAP), which can be 
measured by colorimetric assay.
Cellular cycle analysis
Transfected and harvested cells were permeabilized by 
using ethanol 70% in ice and then the DNA was stained with 
propidium iodide (PI)/RNAse A solution (Life Technologies). 
Cellular cycle analysis, including the evaluation of the 
percentage of cells in the G0/G1, S, and G2/M phases of 
the cell cycle, was performed by flow cytometry (BD FACS 
Calibur) only on transfected GFP+ cells, and analyzed by 
using the ModFIT and GraphPad softwares.
The production level of cyclin A (known to be 
crucial for cell cycle progression) was also evaluated 
by staining the permeabilized cells with the following 
antibody: CST 8607S; PE Mouse Anti-Human Cyclin A 
Set BD 550913.
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